Cargando…

2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region

The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y(12) inhibitors (i.e. ticagrelor and prasugrel) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jack WC, Chew, Derek P, Abdul Kader, Muhamad Ali SK, Ako, Junya, Bahl, Vinay K, Chan, Mark, Park, Kyung Woo, Chandra, Praveen, Hsieh, I-Chang, Huan, Do Quang, Johar, Sofian, Juzar, Dafsah Arifa, Kim, Byeong-Keuk, Lee, Cheol Whan, Lee, Michael Kang-Yin, Li, Yi-Heng, Almahmeed, Wael, Sison, Eric Oliver, Tan, Doreen, Wang, Yu-Chen, Yeh, Shiuan Jong, Montalescot, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941380/
https://www.ncbi.nlm.nih.gov/pubmed/33708263
http://dx.doi.org/10.15420/ecr.2020.40
_version_ 1783662143038554112
author Tan, Jack WC
Chew, Derek P
Abdul Kader, Muhamad Ali SK
Ako, Junya
Bahl, Vinay K
Chan, Mark
Park, Kyung Woo
Chandra, Praveen
Hsieh, I-Chang
Huan, Do Quang
Johar, Sofian
Juzar, Dafsah Arifa
Kim, Byeong-Keuk
Lee, Cheol Whan
Lee, Michael Kang-Yin
Li, Yi-Heng
Almahmeed, Wael
Sison, Eric Oliver
Tan, Doreen
Wang, Yu-Chen
Yeh, Shiuan Jong
Montalescot, Gilles
author_facet Tan, Jack WC
Chew, Derek P
Abdul Kader, Muhamad Ali SK
Ako, Junya
Bahl, Vinay K
Chan, Mark
Park, Kyung Woo
Chandra, Praveen
Hsieh, I-Chang
Huan, Do Quang
Johar, Sofian
Juzar, Dafsah Arifa
Kim, Byeong-Keuk
Lee, Cheol Whan
Lee, Michael Kang-Yin
Li, Yi-Heng
Almahmeed, Wael
Sison, Eric Oliver
Tan, Doreen
Wang, Yu-Chen
Yeh, Shiuan Jong
Montalescot, Gilles
author_sort Tan, Jack WC
collection PubMed
description The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y(12) inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y(12) inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed.
format Online
Article
Text
id pubmed-7941380
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-79413802021-03-10 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region Tan, Jack WC Chew, Derek P Abdul Kader, Muhamad Ali SK Ako, Junya Bahl, Vinay K Chan, Mark Park, Kyung Woo Chandra, Praveen Hsieh, I-Chang Huan, Do Quang Johar, Sofian Juzar, Dafsah Arifa Kim, Byeong-Keuk Lee, Cheol Whan Lee, Michael Kang-Yin Li, Yi-Heng Almahmeed, Wael Sison, Eric Oliver Tan, Doreen Wang, Yu-Chen Yeh, Shiuan Jong Montalescot, Gilles Eur Cardiol APSC Consensus Statements The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y(12) inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. However, low numbers of Asian patients participated in pivotal studies and few regional studies comparing DAPTs have been conducted. This article aims to summarise current evidence on the use of newer generation P2Y(12) inhibitors in Asian patients with acute coronary syndrome and provide recommendations to assist clinicians, especially cardiologists, in selecting a DAPT regimen. Guidance is provided on the management of ischaemic and bleeding risks, including duration of therapy, switching strategies and the management of patients with ST-elevation and non-ST-elevation MI or those requiring surgery. In particular, the need for an individualised DAPT regimen and considerations relating to switching, de-escalating, stopping or continuing DAPT beyond 12 months are discussed. Radcliffe Cardiology 2021-03-02 /pmc/articles/PMC7941380/ /pubmed/33708263 http://dx.doi.org/10.15420/ecr.2020.40 Text en Copyright © 2021, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle APSC Consensus Statements
Tan, Jack WC
Chew, Derek P
Abdul Kader, Muhamad Ali SK
Ako, Junya
Bahl, Vinay K
Chan, Mark
Park, Kyung Woo
Chandra, Praveen
Hsieh, I-Chang
Huan, Do Quang
Johar, Sofian
Juzar, Dafsah Arifa
Kim, Byeong-Keuk
Lee, Cheol Whan
Lee, Michael Kang-Yin
Li, Yi-Heng
Almahmeed, Wael
Sison, Eric Oliver
Tan, Doreen
Wang, Yu-Chen
Yeh, Shiuan Jong
Montalescot, Gilles
2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title_full 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title_fullStr 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title_full_unstemmed 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title_short 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region
title_sort 2020 asian pacific society of cardiology consensus recommendations on the use of p2y(12) receptor antagonists in the asia-pacific region
topic APSC Consensus Statements
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941380/
https://www.ncbi.nlm.nih.gov/pubmed/33708263
http://dx.doi.org/10.15420/ecr.2020.40
work_keys_str_mv AT tanjackwc 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT chewderekp 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT abdulkadermuhamadalisk 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT akojunya 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT bahlvinayk 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT chanmark 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT parkkyungwoo 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT chandrapraveen 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT hsiehichang 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT huandoquang 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT joharsofian 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT juzardafsaharifa 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT kimbyeongkeuk 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT leecheolwhan 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT leemichaelkangyin 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT liyiheng 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT almahmeedwael 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT sisonericoliver 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT tandoreen 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT wangyuchen 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT yehshiuanjong 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion
AT montalescotgilles 2020asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregion